Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Function:
This product is used in combination with other antiretroviral drugs to treat HIV-1 infection in adults and children over 12 years old (inclusive).
Dosage:
For adults and pediatric patients over 12 years old (inclusive) and weighing 35kg or more, the recommended dose of this product is to take one tablet orally once a day, with food or alone. Dose Adjustment in Patients with Renal Impairment: Drug exposure is significantly increased when emtricitabine or tenofovir disoproxil fumarate is administered to patients with moderate to severe renal impairment. For patients with baseline creatinine clearance between 30 and 49 mL/min, the dosing interval of emtricitabine and tenofovir should be adjusted as recommended. The dosing intervals recommended here are based on modeling of single-dose pharmacokinetic data in non-HIV-infected patients. The safety and efficacy of these dosing interval adjustment recommendations have not been clinically evaluated in patients with moderate to severe renal impairment, so clinical response to treatment and renal function should be closely monitored in these patients. In patients with mild renal impairment, no dose adjustment is necessary (creatinine clearance 50-80 mL/minute). No data are available to provide dosage recommendations for pediatric patients with renal impairment. Doses in patients with changes in creatinine clearance need to be adjusted according to physician recommendations, and patients with mild renal impairment should have calculated creatinine clearance and serum phosphorus concentrations regularly monitored.
Adverse reactions:
Immune system disorders: allergic reactions, including angioedema; Metabolic and nutritional disorders: lactic acidosis, hypokalemia, hypophosphatemia; Respiratory, thoracic and mediastinal disorders: dyspnea; Gastrointestinal disorders: pancreatitis, Increased amylase and abdominal pain; Hepatobiliary disorders: fatty liver, hepatitis, elevated liver enzymes (most common AST, ALT, GGT); Skin and subcutaneous tissue disorders: rash; Musculoskeletal and connective tissue disorders: rhabdomyolysis, osteomalacia (manifested by bone pain, possibly fractures), muscle weakness, myopathy; renal and urinary diseases: acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal tubulopathy, interstitial nephritis ( including acute cases), nephrogenic diabetes insipidus, renal insufficiency, elevated creatinine, proteinuria, polyuria; Systemic and administration site disorders: Asthenia; The following adverse reactions (already listed under the body systems heading above), May be caused by proximal tubular pathology: rhabdomyolysis, osteomalacia, hypokalemia, myasthenia, myopathy, hypophosphatemia.
Drug contraindications:
If allergic to this product, it is prohibited to use during lactation. Use with caution in children. Use with caution in children with renal impairment.